Eisai forecasts Leqembi sales JPY 300B

BioArctic's partner Eisai published a presentation simulating potential future sales for Lecanemab, projecting sales of approximately JPY 300 billion (SEK 17.6 billion) for the company's fiscal year 2028, ending March 2029. Lecanemab, a drug for early Alzheimer's disease, is the result of a strategic research alliance between BioArctic and Eisai. It is approved in 53 countries, with intravenous and subcutaneous maintenance dosing approved in several key markets including the United Kingdom, China, the United States, and Japan. Recent regulatory advancements include a new drug application for subcutaneous formulation in Japan, inclusion in China's 'Commercial Insurance Innovative Drug List', Priority Review by the United States — Food and Drug Administration in the United States for a subcutaneous starting dose, and acceptance for priority review of a subcutaneous formulation application in China. Clinical studies, such as AHEAD 3-45 and Tau NexGen, involving Lecanemab are ongoing, with collaborations including Biogen, the Alzheimer's Clinical Trial Consortium, and Washington University in St. Louis.